Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience
| Autor: | E. Montserrat, J. L. López-Lorenzo, F. Manso, A. Martín, E. Prieto, J. Arias-Sampedro, M. N. Fernández, F. J. Oyarzábal, J. Odriozola, A. Alcalá, J. García-Conde, E. Conde, R. Guardia, F. Bosch |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Cancer Research
medicine.medical_specialty Antimetabolites Antineoplastic Fever Chronic lymphocytic leukemia Graft vs Host Disease Infections Gastroenterology Internal medicine Cause of Death medicine B-cell chronic lymphocytic leukemia Humans In patient Life Tables Severe toxicity Retrospective Studies Salvage Therapy business.industry Remission Induction Refractory Disease Transfusion Reaction Hematology medicine.disease Hematologic Diseases Leukemia Lymphocytic Chronic B-Cell Survival Analysis Fludarabine Treatment Outcome Oncology Spain Toxicity Drug Evaluation Anemia Hemolytic Autoimmune business Previously treated Vidarabine medicine.drug |
| Zdroj: | Leukemialymphoma. 21(5-6) |
| ISSN: | 1042-8194 |
| Popis: | Fludarabine produces high response rates in patients with B-cell chronic lymphocytic leukemia (CLL). Nevertheless, response to fludarabine of patients with previously treated CLL varies from 17% to 74% (0% to 38% CR). In 68 patients with heavily pretreated and advanced CLL, an overall response rate to fludarabine of 28% (4% CR) was observed. Response correlated with sensitivity of the disease to previous treatments (relapsing vs. refractory disease) (62% vs. 20%; p = 0.005) and, albeit not significantly, with the number of cycles of fludarabine (3 vs.or = 3) that patients could receive (36% vs. 15%; p = NS). Responding patients had a longer survival (median, not reached) than those not responding (median, 11 months) (p = 0.03). Severe toxicity was observed in some cases. It is concluded that fludarabine is a highly useful agent in CLL. However, in order to improve its effectiveness and decrease its toxicity, fludarabine should be given as soon as a lack of response to front-line therapy is observed and before the disease becomes completely resistant to therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|